Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. – PubMed

Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. - PubMed

Forty patients with invasive cancer of cervix from New Delhi were examined for the presence of human papillomavirus (HPV) and herpes simplex virus (HSV) type 2 DNA sequences in a Southern hybridization assay. Deletions or mutations of essential HSV-1 genes (e.g. When anti-apoptotic pathways are suppressed, this balance is upset and the cells die by apoptosis, referred to here as HSV-1-dependent apoptosis (HDAP). In addition, the growth characteristics of G207 were assessed. No significant difference in HSV-1 reactivation was found before and after chemotherapy. . CD8+ cytotoxic T lymphocyte (CTL) activity was generated that recognized a dominant “tumor-specific” major histocompatibility complex (MHC) class I-restricted epitope (AH1) from CT26 cells.
Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. - PubMed

Oncolytic herpes simplex virus type-1 (HSV-1) is a promising cancer therapy approach, which utilizes the cytolytic replication cycle of the virus to specifically kill tumor cells (oncolysis).8, 9 A wild-type HSV-1 cannot be used for cancer therapy because it lacks tumor specificity and is toxic to normal healthy tissues. Quality assessment was carried out on randomisation, blindness, withdrawals and selective reporting. The Cochrane Collaboration’s statistical guidelines were followed and risk ratio (RR) values were calculated using random-effects models. Seventeen trials satisfied the inclusion criteria. Four trials evaluated preventative interventions for HSV lesions, three trials for viral isolates, and eight trials evaluated both outcome measures. The efficacy of mutant HSV has been demonstrated preclinically in pediatric gliomas, medulloblastomas, and neuroblastomas (22,23,24,25). Two trials evaluating treatment reported on time to healing, duration of viral shedding and relief of pain.

No trials reported on duration of hospital stay, amount of analgesia or patient quality of life.In placebo controlled trials, aciclovir was found to be effective for the prevention of HSV infections as measured by oral lesions or viral isolates (RR = 0.16, 95% confidence interval (CI) 0.08 to 0.31 nine trials; RR = 0.17, 95% CI 0.07 to 0.37 nine trials). There is no evidence that valaciclovir is more efficacious than aciclovir, or that higher doses of valaciclovir are more effective than lower doses. Placebo was found to be more effective than prostaglandin E for prevention of viral isolates (RR = 1.87, 95% CI 1.12 to 3.14 one trial).Aciclovir was also found to be effective for the treatment of HSV in terms of duration of viral shedding (median of 2.5 days versus 17.0 days, P = 0.0002; 2 days compared to more than 9, P = 0.0008), time to first decrease in pain (median 3 days compared to 16, P = 0.04), complete resolution of pain (9.9 days compared to 13.6 days, P = 0.01; median of 6 days compared to 16, P = 0.05), 50% healing (median of 6 days compared to 11, P = 0.01) and total healing (median 13.9 days compared to 20.7 days, P = 0.08; median of 8 days compared to 21, P = 0.0). There is evidence that aciclovir is efficacious in the prevention and treatment of herpes simplex virus infections. However, the replication of CEAICP4 is greatly attenuated even in several CEA-positive cell lines.16 bM24-TE15 and G92A12 also exhibited attenuated replication in permissive cells. There is evidence that as a prophylaxis, placebo is more efficacious than prostaglandin E. However, in all included trials, risk of bias is unclear.

You may also like